TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept in Polypoidal Choroidal Vasculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Men and women ≥50 years of age~* Diagnosis of symptomatic macular Polypoidal Choroidal Vasculopathy (PCV) in the study eye established by Indocyanine Green Angiography(ICGA) at the study center~* Greatest linear dimension of the lesion of \< 5400 mm (approximately, 9 Macular Photocoagulation Study disk areas), assessed by ICGA.~* An Early treatment diabetic retinopathy study (ETDRS) BCVA of 73 to 24 letters in the study eye.~Exclusion Criteria:~* Prior use of intravitreal or sub-tenon corticosteroids in the study eye within 3 months prior to study entry~* Any prior use of intraocular anti Vascular Endothelial Growth Factor (anti-VEGF)agents in the study eye, or systemic use of anti VEGF products within 3 months prior to study entry~* Prior macular laser treatment in the study eye including Photodynamic Therapy (PDT)~* History of allergy to fluorescein used in fluorescein angiography, iodine and/or indocyanine green.~* History of allergy to aflibercept, verteporfin, or their excipients.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept + Sham PDT (Type: EXPERIMENTAL): Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
- Aflibercept + Active PDT (Type: EXPERIMENTAL): Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 18 - 65 years of age.~* Each patient must have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must be considered reliable according to the investigator's clinical judgement~* Patients must fulfill the criteria for recurrent MDD without psychotic features as defined by the DSM-IV, based on clinical assessment and confirmed by Structured Clinical Interview for DSM-IV Axis I Disorders - Clinical Version (SCID-I) plus the Major Depressive Disorder Specifiers included in the Research Version of the SCID-I. This includes at least one of the following diagnoses: 296.31, 296.32, and 296.33~* Female patients of childbearing potential must be using a medically accepted means of contraception throughout the course of the study. Use of any oral or injectable contraception must be initiated prior to visit 2~* Failure to achieve satisfactory antidepressant response to an adequate trial of an antidepressant (except fluoxetine), for at least 6 weeks at an acceptable dose or greater, occurring within the current episode of MDD~Exclusion Criteria:~* Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry~* Exposure to OFC in a Lilly-sponsored clinical trial investigating OFC, and any patients historically failing to respond to olanzapine and fluoxetine in combination under any circumstance~* Persons who have previously entered any Lilly-sponsored study which was investigating olanzapine~* Female patients who are either pregnant or nursing~* Serious, unstable illnesses for which death is anticipated within 1 year of intensive care unit hospitalization for the disease is anticipated within 6 months. This includes hepatic (specifically any degree of jaundice), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic diseases (specifically current agranulocytosis with an absolute neutrophil count \< 500 mm_3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minocycline in Clinically Isolated Syndromes (CIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 60 years.~* First focal clinical episode suggestive of demyelinating disease within the previous 180 days (measured from onset of the first symptom to treatment start), based on the appearance of a neurological abnormality, present for at least 24 hours.~* Objective clinical evidence must be present or documented. Patients will be included irrespective of whether the first clinical demyelinating episode was monosymptomatic (i.e. clinical evidence of a single lesion) or polysymptomatic (i.e. clinical evidence of more than one lesion).~* At least two lesions on the T2-weighted brain MRI\* scan at least one of which is ovoid or periventricular or infratentorial. MRI eligibility will be determined centrally by the UBC MS/MRI Research Group.\*One lesion on spinal MRI may substitute for one brain lesion as per the 2005 McDonald Criteria.~* Sexually active women of child-bearing potential must agree to use adequate contraception.~* Written informed consent~Exclusion Criteria:~* Any disease other than MS that could better explain the patient's signs and symptoms.~* Any previous clinical event reasonably attributable to acute demyelination, regardless of whether medical attention was obtained.~* Complete transverse myelitis or bilateral optic neuritis. A waiver can be obtained for bilateral optic neuritis but must be obtained prior to randomization. Waivers must be approved by 3 neurologists including a member of the Clinical Eligibility / Endpoint Committee, a member of the DSMC, and by an experienced MS neurophthalmologist.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: ACTIVE_COMPARATOR): Minocycline 100 mg oral for up to 24 months
- Placebo (Type: PLACEBO_COMPARATOR): Lactose Monohydrate NF (Spray-dried) 235 mg/cap Magnesium Stearate NF 1 mg/cap Croscarmellose Sodium NF 4 mg/cap Stearic Acid 10 mg/cap Placebo CAP Lt orange OP-Purple OP (APO 100)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with nonmyeloid malignancy(ies)~* Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy~Exclusion Criteria:~* Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS)~* Unstable cardiac disease or anemia due to other causes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe Crohn's Disease confirmed by endoscopy or radiologic evaluation for greater than 4 months (16 weeks)~* Inadequate response to conventional therapy for Crohn's Disease~* Subjects \>=18 and \<=75 years of age and in good health (Investigator discretion) with a recent stable medical history~* Harvey Bradshaw Index score of 7 or higher~Exclusion Criteria:~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Subject who has had surgical bowel resections within the past 6 months or is planning any resection at any time point while enrolled in the study~* Female subject who is pregnant or breast-feeding or considering becoming pregnant~* Previous treatment with adalimumab or previous participation in an adalimumab clinical study~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Subjects with any prior exposure to Tysabri® (natalizumab)~* Subjects on prednisone \>40 mg/day (or equivalent), subjects on budesonide \>9 mg/day, or subjects who are taking prednisone and budesonide concurrently at Baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~INCLUSION CRITERIA FOR INITIAL STUDY ENROLLMENT:~Patients will be eligible for initial enrollment on this study as long as they meet the following criteria:~* Diagnosis of acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, myeloproliferative disorder, Hodgkin lymphoma, non-Hodgkin lymphoma or non-malignant disease requiring allogeneic HSCT~* Birth to age 70 years of age~* Study entry consent is signed and faxed to Research Coordinator~INCLUSION CRITERIA AT TIME OF IL-2 ADMINISTRATION:~* At least day +7 post transplant~* Less than or equal to 30 days post transplant~* Lansky or Karnofsky score greater than or equal to 50%~* Total bilirubin less than or equal to 1.5mg/dL~* Alanine aminotransferase level (ALT) less than or equal to five times normal, serum direct bilirubin less than or equal to 1.5mg/dL, albumin greater than or equal to 3.0gm/dL~* Serum creatinine less than three times normal or creatinine clearance greater than 80mg/min/1.73m2~* Ensure that informed consent signed and faxed to Research Coordinator~EXCLUSION CRITERIA:~EXCLUSION CRITERIA AT TIME OF IL-2 ADMINISTRATION:~Patients will be ineligible to receive IL-2 injections if any of the following is true:~* Active, acute GVHD greater than or equal to grade II~* Serious, active bacterial, fungal or viral infection (i.e. intensive care)~* Clinical Signs of severe pulmonary dysfunction~* Clinical Signs of sever cardiac dysfunction~* Receiving corticosteroids as GVHD treatment~* Hypersensitivity or allergy to IL-2

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IL2 Administration (Type: EXPERIMENTAL): SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.~Time will be measured as 'week beginning with first IL-2 injection.'~T cell Induction via IL-2 to reduce GVHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paraspinal Block in Nonspecific Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Age between 20 to 60 years;~* Clinical symptoms of vertebral pain that is unresponsive to symptomatic treatment with anti-inflammatory drugs for 3 months;~* Moderate to severe pain: visual analog scale (VAS) \> 4;~* Diagnosis of chronic nonspecific low back pain;~* MiniMental test (MEEM) between 24 and 30;~* Availability to comply with the visits;~* Agree with signing the Informed Consent Form~Exclusion criteria:~* Severe psychiatric disease that requires psychiatric care;~* Neurological disorders (lumbosciatic pain);~* Concurrent fibromyalgia, per the 1990 diagnostic criteria of the American Academy of Rheumatology~* Concurrent rheumatic disease~* History of allergy to lidocaine (used for paraspinal blocks)~* Labor problems~* History of surgery on the lumbar spine~* No availability to visit the clinic for treatment and evaluations.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
- Sham lidocaine (Type: SHAM_COMPARATOR): Sham Injection, without lidocaine, combined with standard treatment.
- Standard treatment only (Type: ACTIVE_COMPARATOR): The only intervention is the standard treatment. No lidocaine or shame injection was used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women 16 or older in UK(except Northern Ireland) sites, 17 years or more in Northern Ireland (UK) and 18 years or more in Ireland and US~* present within 120 hours of unprotected intercourse~* regular menstrual cycles~* No current use of hormonal contraception~* Willing to not use hormonal methods of contraception until study completion~* At least one complete menstrual cycle (2 menses) post miscarriage, delivery or abortion~* For women who present more than 72 hours after intercourse, decline the insertion of an Intra Uterine Device for emergency contraception~* Able to provide informed consent~* Willing to abstain from further acts of unprotected intercourse until study completion~Exclusion Criteria:~* One or more acts of unprotected intercourse more than 120 hours~* current or recent use of hormonal methods of contraception~* currently pregnant or breastfeeding~* tubal ligation or current use of IUD~* Use of hormonal emergency contraception since last menstrual period~* Current use of IUD~* Tubal ligation~* Partner with a vasectomy~* Unsure about the date of the last menstrual period~* Severe asthma insufficiently controlled by oral glucocorticoid~* Hypersensitivity to the active substance levonorgestrel or any of the excipients of the drug products used in the study

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDB-2914 (Type: EXPERIMENTAL): None
- Levonorgestrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal Aerosol Chemotherapy in Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age above 18 years~* written, informed consent~* presence of peritoneal carcinomatosis~Exclusion Criteria:~* language barrier~* parenchymal metastases~* unability to undergo laparoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intraperitoneal Chemotherapy (Type: EXPERIMENTAL): Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years old with proven advanced solid tumors not amenable to any clinical improvement by current standard treatments. Tumors recognized to be highly vascularized (e.g. renal, colon thyroid and head and neck cancers), will be included.~* ECOG Performance status 0 - 2~* Patients may have had prior therapy providing the following conditions are met:~  * Chemo, radio, hormonal or immunotherapy: wash-out period of 28 days~ * Surgery: wash-out period of 14 days~* Adequate baseline bone marrow, hepatic and renal function, defined as follows:~* Neutrophils \> 1.5 x 10\^9/L and platelets \> 100 x 10\^9/L~* Bilirubin \< 1.5 x ULN~* AST and/or ALT \< 2.5 x ULN in absence of liver metastases~* AST and/or ALT \< 5 x ULN in presence of liver metastases~* Serum creatinine \< 1.5 x ULN~* Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (reference appendix Technical data sheet human albumin)~* Normal cardiac function and absence of uncontrolled hypertension~* Patients must give written informed consent to participate in the study~Exclusion Criteria:~* Concurrent anticancer therapy~* Patients may not receive any other investigational agents while on study~* Clinical signs of CNS involvement~* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol~* Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol~* Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm A (Type: EXPERIMENTAL): Patients were scheduled to receive a 1 hour intravenous (iv) infusion of NGR-hTNF every 3weeks.- The dose of administered NGR-hTNF was: 0.2, 0.4, 0.8, 1.6 μg/m2 (step 1); 3.2, 6.4, 12.8 μg/m2 (step 2); 19.2, 28.8, 43.2 64.8 μg/m2 (step 3); 86.2, 114.6, 152.4 μg/m2 (step 4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine for Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided informed consent prior to any study specific procedures~* Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) manic or mixed type with or without psychotic symptoms~* Voluntarily hospitalized for current manic episode~* Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG)~Exclusion Criteria:~* Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine (Type: EXPERIMENTAL): Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete